Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
33 hedge funds and large institutions have $52.8M invested in Astria Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more funds holding
Funds holding: 33 → 33 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
35% less capital invested
Capital invested by funds: $81.4M → $52.8M (-$28.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$858K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$670K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$230K |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$223K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$357K |
| 2 |
FAM
Fred Alger Management
New York
|
-$247K |
| 3 |
Millennium Management
New York
|
-$205K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$107K |
| 5 |
D.E. Shaw & Co
New York
|
-$70.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $13K | +$15.2K | +44 | New |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $9K | +$11.7K | +34 | New |
|
|
BA
28
BlackRock Advisors
Wilmington,
Delaware
| $8K | +$5.51K | +16 | +178% |
|
|
SO
29
STRS Ohio
Columbus,
Ohio
| $7K | – | – | – |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | -$2.76K | -8 | -42% |
|
31
Morgan Stanley
New York
| $3K | +$2.07K | +6 | +300% |
|
32
Wells Fargo
San Francisco,
California
| $1K | +$1.72K | +5 | New |
|
33
Geode Capital Management
Boston,
Massachusetts
| $187 | -$345 | -1 | -0.2% |
|
|
TAM
34
Tocqueville Asset Management
New York
| – | -$357K | -750 | Closed |
|
|
35
Millennium Management
New York
| – | -$205K | -431 | Closed |
|
36
BNP Paribas Financial Markets
Paris,
France
| – | -$5.79K | -12 | Closed |
|
|
PCM
37
Prelude Capital Management
New York
| – | -$3K | -7 | Closed |
|
|
TRCT
38
Tower Research Capital (TRC)
New York
| – | -$2K | -5 | Closed |
|
39
Bank of America
Charlotte,
North Carolina
| – | -$1K | -2 | Closed |
|
ATXS Hedge Fund Activity: Q1 2016 in Review
33 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2016, worth a combined $52.8M — down 35% from $81.4M a quarter earlier.
Fund positioning in ATXS was balanced in Q1 2016: 6 funds opened new positions, 6 closed out, 12 added to existing stakes and 8 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $858K. The largest seller was Tocqueville Asset Management, exiting entirely with an estimated $357K sold.
- 33 institutional investors held Astria Therapeutics (ATXS) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $52.8M of Astria Therapeutics stock for Q1 2016, down 35% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q1 2016 and 6 closed out, a net change of 0 holders.
- The largest Astria Therapeutics buyer in Q1 2016 was Sphera Funds Management, an estimated $858K added.
- The largest Astria Therapeutics seller in Q1 2016 was Tocqueville Asset Management, an estimated $357K sold.
Based on aggregated 13F filings for Q1 2016.